THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 91 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2014. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $92 | -5.2% | 10,856 | 0.0% | 0.00% | – |
| Q1 2024 | $97 | -20.5% | 10,856 | 0.0% | 0.00% | -100.0% |
| Q4 2023 | $122 | -86.1% | 10,856 | -79.4% | 0.00% | -50.0% |
| Q3 2023 | $876 | +682.1% | 52,615 | +384.7% | 0.00% | +100.0% |
| Q2 2023 | $112 | -5.1% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $118 | -3.3% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $122 | -99.9% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $110,000 | +12.2% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $98,000 | -5.8% | 10,856 | 0.0% | 0.00% | – |
| Q1 2022 | $104,000 | -13.3% | 10,856 | 0.0% | 0.00% | – |
| Q4 2021 | $120,000 | +50.0% | 10,856 | 0.0% | 0.00% | – |
| Q3 2021 | $80,000 | -49.4% | 10,856 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $158,000 | -28.8% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $222,000 | +15.0% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $193,000 | +19.9% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $161,000 | -29.4% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $228,000 | -9.2% | 10,856 | 0.0% | 0.00% | -50.0% |
| Q1 2020 | $251,000 | -10.7% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $281,000 | +33.2% | 10,856 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $211,000 | +19.2% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $177,000 | -28.0% | 10,856 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $246,000 | -11.5% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $278,000 | -21.7% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $355,000 | +44.3% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $246,000 | -6.5% | 10,856 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $263,000 | -15.7% | 10,856 | -2.9% | 0.00% | 0.0% |
| Q4 2017 | $312,000 | -18.5% | 11,175 | 0.0% | 0.00% | -33.3% |
| Q3 2017 | $383,000 | -18.0% | 11,175 | -4.7% | 0.00% | 0.0% |
| Q2 2017 | $467,000 | +8.1% | 11,728 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $432,000 | +11.9% | 11,728 | -3.1% | 0.00% | 0.0% |
| Q4 2016 | $386,000 | -12.1% | 12,100 | 0.0% | 0.00% | -25.0% |
| Q3 2016 | $439,000 | +59.6% | 12,100 | 0.0% | 0.00% | +100.0% |
| Q2 2016 | $275,000 | +5.4% | 12,100 | -12.7% | 0.00% | 0.0% |
| Q1 2016 | $261,000 | -4.4% | 13,864 | -16.7% | 0.00% | 0.0% |
| Q4 2015 | $273,000 | +49.2% | 16,641 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $183,000 | -24.7% | 16,641 | -10.7% | 0.00% | 0.0% |
| Q2 2015 | $243,000 | -24.8% | 18,635 | 0.0% | 0.00% | -33.3% |
| Q1 2015 | $323,000 | +11.0% | 18,635 | -4.4% | 0.00% | +50.0% |
| Q4 2014 | $291,000 | +114.0% | 19,502 | +231.3% | 0.00% | +100.0% |
| Q3 2014 | $136,000 | -27.7% | 5,887 | 0.0% | 0.00% | -50.0% |
| Q2 2014 | $188,000 | – | 5,887 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
| Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
| Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
| Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
| Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
| Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
| Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
| Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |